AstraZeneca reached a drug‑pricing agreement with the White House similar in structure to the one struck by Pfizer last week, sources reported. The company has agreed to extend portfolio discounts under the administration’s most‑favored‑nation style negotiating framework, officials said, with details to be announced by federal officials. Media reports indicated the pact follows intensified executive pressure on pharma pricing and signals the administration’s continued willingness to secure voluntary deals with major manufacturers. Company spokespeople acknowledged discussions and said they were cooperating with policymakers on improving patient access while balancing commercial considerations. Industry commentators cautioned the deals could raise questions about precedent and competitive positioning for companies that do not sign similar agreements, and that downstream effects on payer negotiations and global pricing may follow.